Serum biomarkers and the risk of pancreatic cancer in a prospective study

• Project/Area Number: 20790450
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Public health/Health science
• Research Institution: Aichi Medical University
• Principal Investigator: LIN Yingsong Aichi Medical University, 医学部, 准教授 (50340302)
• Project Period (FY): 2008 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000); Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 膵がん / 血清バイマーカー / リスク / コホート内症例対照研究 / 血清マーカー

Research Abstract

The associations of serum TGF-β1, CRR, and anti-H. pylori antibody with the risk of pancreatic cancer death were exalrlined in a nested case-control study within the Japan Collaborative Cohort Study. Elevated baseline serum TGF-β1 was associated with an increased risk of pancreatic cancer death. Serum CRP was higher among cases than among control subjects. Overall no associations were observed between H.pylori infection, serum CRP and pancreatic cancer risk.